BioMarin Pharmaceutical Inc.SEC Filings
|
|
All SEC filings by BioMarin Pharmaceutical Inc. (BMRN) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 6, 2026 | |
| 10-Q | Quarterly report | View Diff | May 5, 2026 | |
| ARS | Annual report to shareholders | Apr 21, 2026 | ||
| 10-K | Annual report | View Diff | Feb 26, 2026 | |
| 10-Q | Quarterly report | View Diff | Oct 28, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 5, 2025 | |
| 10-Q | Quarterly report | View Diff | May 2, 2025 | |
| ARS | Annual report to shareholders | Apr 8, 2025 | ||
| 10-K | Annual report | View Diff | Feb 24, 2025 | |
| 10-Q | Quarterly report | View Diff | Oct 31, 2024 |
Events
| 8-K | Current report | Oct 6, 2026 | ||
| 8-K | Current report | Sep 30, 2026 | ||
| 8-K | Current report | Sep 15, 2026 | ||
| 8-K | Current report | Sep 14, 2026 | ||
| 8-K | Current report | Sep 1, 2026 | ||
| 8-K | Biomarin Announces Global Settlement with Ascendis Pharma A/s; Ascendis Will Pay Royalties to Biomarin on Yuviwel Sales in U.s., Eu, Brazil and South Korea | Aug 31, 2026 | ||
| 8-K | Biomarin to Acquire Alesta Therapeutics to Gain Ale1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to Biomarins Pipeline | Aug 18, 2026 | ||
| 8-K | Biomarin Reports Second Quarter 2026 Financial and Operating Results | Aug 6, 2026 | ||
| 8-K/A | Report of Independent Registered Public Accounting Firm | Jul 13, 2026 | ||
| 8-K | Current report | Jun 4, 2026 |
Registrations and Prospectuses
| S-8 | Registration of securities for employees | Aug 6, 2026 | ||
| S-8 | Registration of securities for employees | Aug 5, 2025 | ||
| SC TO-T/A | Third party tender offer statement | Jul 1, 2025 | ||
| SC TO-T/A | Third party tender offer statement | Jun 17, 2025 | ||
| SC TO-T/A | Third party tender offer statement | Jun 13, 2025 | ||
| SC TO-T/A | Third party tender offer statement | Jun 4, 2025 | ||
| SC TO-T | Third party tender offer statement | Jun 2, 2025 | ||
| SC TO-C | Information about tender offer | May 19, 2025 | ||
| SC TO-C | Information about tender offer | May 16, 2025 | ||
| SC TO-C | Information about tender offer | May 16, 2025 |
Proxies
| DEFA14A | Proxy Filing | Apr 21, 2026 | ||
| DEF 14A | Annual Meeting of Shareholders | View Diff | Apr 21, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Apr 8, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 8, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Apr 9, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 9, 2024 | |
| DEFA14A | Additional proxy soliciting materials | Apr 11, 2023 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 11, 2023 | |
| DEFA14A | Additional proxy soliciting materials | Apr 12, 2022 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 12, 2022 |
Other
| CORRESP | Correspondence with SEC | Jun 13, 2025 | ||
| UPLOAD | Letter from SEC | Oct 3, 2024 | ||
| CORRESP | Correspondence with SEC | Sep 16, 2024 | ||
| UPLOAD | Letter from SEC | Sep 2, 2024 | ||
| UPLOAD | Letter from SEC | Apr 10, 2023 | ||
| CORRESP | Correspondence with SEC | Apr 6, 2023 | ||
| UPLOAD | Letter from SEC | Mar 30, 2023 | ||
| UPLOAD | Letter from SEC | Mar 29, 2022 | ||
| CORRESP | Correspondence with SEC | Feb 23, 2022 | ||
| UPLOAD | Letter from SEC | Jan 31, 2022 |
Ownership
| 4 | Friberg Gregory R | Oct 1, 2026 | ||
| 4 | Plenge Robert M | Sep 14, 2026 | ||
| 3 | Plenge Robert M | Sep 14, 2026 | ||
| 4 | Davis George Eric | Sep 3, 2026 | ||
| 144 | Notice of proposed sale of securities | Sep 2, 2026 | ||
| 4 | Countouriotis Athena | Jun 4, 2026 | ||
| 4 | Walbert Timothy P | Jun 4, 2026 | ||
| 4 | Ho Maykin | Jun 4, 2026 | ||
| 4 | Hombach Robert J. | Jun 4, 2026 | ||
| 4 | Enyedy Mark J | Jun 4, 2026 |